| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 16:16:29 UTC |
|---|
| Update Date | 2021-09-26 23:11:23 UTC |
|---|
| HMDB ID | HMDB0256021 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Oxyphenbutazone |
|---|
| Description | Oxyphenbutazone, also known as oxi-fenibutol or oxifenbutazona, belongs to the class of organic compounds known as 1-hydroxy-2-unsubstituted benzenoids. These are phenols that are unsubstituted at the 2-position. Oxyphenbutazone is a secondary metabolite. Secondary metabolites are metabolically or physiologically non-essential metabolites that may serve a role as defense or signalling molecules. In some cases they are simply molecules that arise from the incomplete metabolism of other secondary metabolites. Based on a literature review a significant number of articles have been published on Oxyphenbutazone. This compound has been identified in human blood as reported by (PMID: 31557052 ). Oxyphenbutazone is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Oxyphenbutazone is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1 InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione | ChEBI | | 1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine | ChEBI | | 1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-N-butylpyrazolidine | ChEBI | | 3,5-Dioxo-1-phenyl-2-(p-hydroxyphenyl)-4-N-butylpyrazolidene | ChEBI | | 4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione | ChEBI | | 4-Butyl-1-(p-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione | ChEBI | | 4-Butyl-2-(4-hydroxyphenyl)-1-phenyl-3,5-dioxopyrazolidine | ChEBI | | 4-Butyl-2-(p-hydroxyphenyl)-1-phenyl-3,5-pyrazolidinedione | ChEBI | | Hydroxyphenylbutazon | ChEBI | | Oxi-fenibutol | ChEBI | | Oxifenbutazona | ChEBI | | Oxifenylbutazon | ChEBI | | Oxiphenbutazonum | ChEBI | | Oxyphenbutazonum | ChEBI | | Oxyphenylbutazone | ChEBI | | p-Hydroxyphenylbutazone | ChEBI | | p-Oxyphenylbutazone | ChEBI | | Reozon | Kegg | | Tanderil | MeSH | | Belmac brand OF oxyphenbutazone | MeSH | | Diflamil | MeSH | | Hydroxyphenylbutazone | MeSH | | Novartis ophthalmics brand OF oxyphenbutazone | MeSH |
|
|---|
| Chemical Formula | C19H20N2O3 |
|---|
| Average Molecular Weight | 324.3737 |
|---|
| Monoisotopic Molecular Weight | 324.147392516 |
|---|
| IUPAC Name | 4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione |
|---|
| Traditional Name | oxyphenbutazone |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3 |
|---|
| InChI Key | HFHZKZSRXITVMK-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 1-hydroxy-2-unsubstituted benzenoids. These are phenols that are unsubstituted at the 2-position. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Phenols |
|---|
| Sub Class | 1-hydroxy-2-unsubstituted benzenoids |
|---|
| Direct Parent | 1-hydroxy-2-unsubstituted benzenoids |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1-hydroxy-2-unsubstituted benzenoid
- Monocyclic benzene moiety
- Pyrazolidinone
- 1,3-dicarbonyl compound
- Pyrazolidine
- Carboxylic acid hydrazide
- Azacycle
- Organoheterocyclic compound
- Carboxylic acid derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Organic nitrogen compound
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Predicted by Siyang on May 30, 2022 | 18.1442 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.54 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3120.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 482.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 211.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 239.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 492.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 813.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 700.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 75.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1616.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 563.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1787.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 516.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 456.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 379.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 174.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 19.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - Oxyphenbutazone EI-B (Non-derivatized) | splash10-0006-9601000000-0e93b2309b6f4ff21792 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Oxyphenbutazone GC-MS (Non-derivatized) - 70eV, Positive | splash10-054k-8791000000-637b7e1dbae4d383b921 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Oxyphenbutazone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Oxyphenbutazone GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Oxyphenbutazone GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxyphenbutazone , positive-QTOF | splash10-0002-3920000000-8a5be556648d9ff3213b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxyphenbutazone 10V, Positive-QTOF | splash10-004i-1129000000-635a75af02145840f4c6 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxyphenbutazone 20V, Positive-QTOF | splash10-004i-7396000000-7af7a18b0ccfe9a692b8 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxyphenbutazone 40V, Positive-QTOF | splash10-00kf-9300000000-beaa3a49e9b7a30e7df1 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxyphenbutazone 10V, Negative-QTOF | splash10-00di-0119000000-982c7f5b104baf102d43 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxyphenbutazone 20V, Negative-QTOF | splash10-00dj-6698000000-2933626114d1b33aada5 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxyphenbutazone 40V, Negative-QTOF | splash10-0a4p-7900000000-77b1ac23e35e6cb8ed59 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|